STOK Pengajuan SEC - Stoke Therapeutics, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	549300RD25SS2DIJHJ67
CIK	1623526

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Stoke Therapeutics, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 12, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 7.01 Regulation FD. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commissio
August 12, 2025	EX-10.3	Interim Executive Chair Agreement, dated March 16, 2025, between Dr. Arthur O. Tzianabos, Ph.D. and the Registrant. Exhibit 10.3 March 16, 2025 Arthur Tzianabos Dear Arthur: On behalf of Stoke Therapeutics, Inc. (the “Company”), this letter agreement (the “Agreement”) sets forth the terms and conditions of your appointment as Interim Executive Chairman of the Company’s Board of Directors. 1. Position; Continued Board Service. Effective as of March 19, 2025 (the “Start Date”), you will be appointed as the Compan
August 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.
August 12, 2025	EX-99.1	Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates – First patient dosed in the Phase 3 EMPEROR study of zorevunersen in patients with Dravet syndrome – – New 3-year zorevunersen OLE data provide additional EX 99.1 Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates – First patient dosed in the Phase 3 EMPEROR study of zorevunersen in patients with Dravet syndrome – – New 3-year zorevunersen OLE data provide additional support for disease modification: continuing and durable reductions in seizures and improvements in cognition and behavior and generally well
August 12, 2025	EX-10.2	Interim Chief Executive Officer Agreement, dated March 16, 2025, between Ian F. Smith and the Registrant. Exhibit 10.2 March 16, 2025 Ian F. Smith Dear Ian: On behalf of Stoke Therapeutics, Inc. (the “Company”), this letter agreement (the “Agreement”) sets forth the terms and conditions of your appointment as Interim Chief Executive Officer of the Company. 1. Position; Continued Board Service. Effective as of March 19, 2025 (the “Start Date”), you will be appointed as the Company’s Interim Chief Execu
August 12, 2025	EX-99.2	Stoke Therapeutics Second Quarter 2025 Business Update Webcast for Investors & Analysts August 12, 2025 Stoke Therapeutics Second Quarter 2025 Business Update Webcast for Investors & Analysts August 12, 2025 Long-Term 36-Month OLE Data Kimberly Parkerson, M.
August 12, 2025	EX-10.1	Transition and Separation Agreement, dated March 16, 2025, between Dr. Edward M. Kaye, M.D. and the Registrant. Exhibit 10.1 March 16, 2025 VIA E-MAIL Edward Kaye Re: Terms of Resignation Dear Ed: This letter confirms the agreement (“Agreement”) between you and Stoke Therapeutics, Inc. (the “Company”) concerning the terms of your resignation and offers you the separation compensation we discussed in exchange for a general release of claims and covenant not to sue. 1. Resignation Date: March 19, 2025, is you
August 11, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 Stoke Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commissio
August 11, 2025	EX-99.1	Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome – Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compare EX-99.1 Exhibit 99.1 Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome – Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period – – Dravet syndrome is a rare genetic disease characterized by refractory seizures and
July 10, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2025 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission
July 10, 2025	EX-99.1	Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress – Data from an analysis designed to evaluate Exhibit 99.1 Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress – Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findi
July 9, 2025	EX-4.2	Form of Debt Security Exhibit 4.2 FORM OF DEBT SECURITY [Face of Security] STOKE THERAPEUTICS, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIE
July 9, 2025	CORRESP	STOKE THERAPEUTICS, INC. 45 Wiggins Avenue Bedford, MA 01730 July 9, 2025 CORRESP STOKE THERAPEUTICS, INC. 45 Wiggins Avenue Bedford, MA 01730 July 9, 2025 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Office of Life Sciences Re: Stoke Therapeutics, Inc. Registration Statement on Form S-3 Filed July 9, 2025 File No. 333-288583 Via EDGAR - Acceleration Request Requested Date: July 11
July 9, 2025	S-8	As filed with the Securities and Exchange Commission on July 9, 2025 S-8 As filed with the Securities and Exchange Commission on July 9, 2025 Registration No.
July 9, 2025	EX-99.1	Amended and Restated 2023 Inducement Plan and forms of award agreements thereunder EX-99.1 Exhibit 99.1 STOKE THERAPEUTICS, INC. 2023 INDUCEMENT PLAN AMENDED: JUNE 2, 2025 1. PURPOSE. The purpose of this Plan is to provide incentives to attract and motivate eligible employees whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries, and Affiliates that exist now or in the future, by offering them an opportunity to parti
July 9, 2025	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 Calculation of Fee Filing Tables Form S-3 (Form Type) Stoke Therapeutics, Inc.
July 9, 2025	EX-4.3	Form of Indenture Exhibit 4.3 STOKE THERAPEUTICS, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 – DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 5 ARTICLE 2 – THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES
July 9, 2025	S-3	As filed with the Securities and Exchange Commission on July 9, 2025. Table of Contents As filed with the Securities and Exchange Commission on July 9, 2025.
July 9, 2025	EX-FILING FEES	Filing Fee Table EXHIBIT 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Stoke Therapeutics, Inc.
June 26, 2025	EX-4.3	STOKE THERAPEUTICS, INC. , as Trustee Dated as of , Exhibit 4.3 STOKE THERAPEUTICS, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 – DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 5 ARTICLE 2 – THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES
June 26, 2025	EX-4.2	FORM OF DEBT SECURITY Exhibit 4.2 FORM OF DEBT SECURITY [Face of Security] STOKE THERAPEUTICS, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIE
June 26, 2025	DRSLTR	Fenwick & West LLP DRSLTR Fenwick & West LLP 555 California Street 12th Floor San Francisco, CA 94104 June 26, 2025 CONFIDENTIAL SUBMISSION VIA EDGAR U.
June 26, 2025	DRS	Confidential Draft Submission No. 1 submitted to the Securities and Exchange Commission on June 26, 2025. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information herein remains str Table of Contents Confidential Draft Submission No. 1 submitted to the Securities and Exchange Commission on June 26, 2025. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGI
June 4, 2025	EX-99.1	Forward-Looking Statements and Other Legal Notices This presentation has been prepared by Stoke Therapeutics, Inc. ( Stoke or us ) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be Exhibit 99.1 Stoke Therapeutics NASDAQ: STOK June 2025 © © COP COPY YR RI IG GH HT T 2 20 02 25 5 \| \| S ST TOKE OKE T TH HER ERA AP PEU EUT TI ICS CS \| \| 1 Forward-Looking Statements and Other Legal Notices This presentation has been prepared by Stoke Therapeutics, Inc. ( Stoke or us ) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or shou
June 4, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission F
June 4, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission F
May 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.
May 13, 2025	EX-10.2	License and Collaboration Agreement, dated as of February 14, 2025, by and between Biogen International GmbH and the Registrant Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED LICENSE AND COLLABORATION AGREEMENT by and between STOKE THERAPEUTICS, INC. and Biogen International GmbH Dated as of February 14, 2025 TABLE OF CONTENTS Page Article 1 DEFINITIONS 1 Artic
May 13, 2025	EX-10.1	2025 Non-Employee Director Compensation Policy Exhibit 10.1 STOKE THERAPEUTICS, INC. (“Company”) Non-Employee Director Compensation Policy Approved as of September 9, 2024 (the “Approval Date”) Amended as of February 12, 2025 Each member of the Board of Directors (the “Board”) of Stoke Therapeutics, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation des
May 13, 2025	EX-99.1	Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates – Regulatory alignment achieved for Phase 3 EMPEROR study of zorevunersen, a potential first-in-class disease-modifying medicine for Dravet syndrome; Study EX 99.1 Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates – Regulatory alignment achieved for Phase 3 EMPEROR study of zorevunersen, a potential first-in-class disease-modifying medicine for Dravet syndrome; Study start anticipated in 2Q 2025 – – Zorevunersen collaboration with Biogen brings leading capabilities for commercializing high value, disease-mo
May 13, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission F
April 22, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (
April 22, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt
March 18, 2025	S-8	As filed with the Securities and Exchange Commission on March 18, 2025 As filed with the Securities and Exchange Commission on March 18, 2025 Registration No.
March 18, 2025	10-K	f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38938 Stoke Therape
March 18, 2025	EX-99.1	Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates – Phase 3 EMPEROR study of zorevunersen, a first-in-class potential disease-modifying medicine for Dravet syndrome, on track to initiate in 2 EX.99.1 Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates – Phase 3 EMPEROR study of zorevunersen, a first-in-class potential disease-modifying medicine for Dravet syndrome, on track to initiate in 2Q 2025 – – As of December 31, 2024, the Company had $246.7 million in cash, cash equivalents, and marketable securities; together with the $16
March 18, 2025	EX-FILING FEES	Filing Fee Table EXHIBIT 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Stoke Therapeutics, Inc.
March 18, 2025	EX-10.20	Form of Irrevocable Payment Election for Non-Employee Directors STOKE THERAPEUTICS, INC. CERTAIN CASH DIRECTOR FEES - FORM OF IRREVOCABLE PAYMENT ELECTION Name: Election Year: [ ] As a non-employee member of the board of directors (the “Board”) of Stoke Therapeutics, Inc. (the “Company”), you are entitled to receive cash fees pursuant to the Company’s Non-Employee Director Compensation Policy (as amended by the Board from time to time, the “Policy”). Pursuant
March 18, 2025	EX-99.2	Stoke Therapeutics Announces CEO Transition Edward M. Kaye, M.D., to Step Down as Chief Executive Officer Director Ian F. Smith Appointed Interim Chief Executive Officer Arthur Tzianabos Appointed Interim Executive Chairman of the Board Board of Dire EX.99.2 Stoke Therapeutics Announces CEO Transition Edward M. Kaye, M.D., to Step Down as Chief Executive Officer Director Ian F. Smith Appointed Interim Chief Executive Officer Arthur Tzianabos Appointed Interim Executive Chairman of the Board Board of Directors Initiates Search for Permanent Chief Executive Officer BEDFORD, Mass., March 18, 2025 – Stoke Therapeutics, Inc. (Nasdaq: STOK) is a bio
March 18, 2025	EX-19.1	Insider Trading Policy Insider Trading Policy Policy Owner: Legal Department Effective Date: February 2, 2023 I.
March 18, 2025	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission
March 18, 2025	EX-4.2	Exhibit 4.2 Exhibit 4.2 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of December 31, 2020, Stoke Therapeutics, Inc. (the “Company,” “we,” or “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following description summarizes the mo
February 18, 2025	EX-99.1	Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments Stoke retains exclus Exhibit 99.1 Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Co
February 18, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commiss
January 7, 2025	EX-99.2	The Potential for Disease Modification in the Treatment of Dravet Syndrome: Clinical Data and Phase 3 Plan Barry Ticho, M.D., Ph.D., FACC, Chief Medical Officer Kimberly Parkerson, M.D., Ph.D., SVP, Head of Neurology Clinical Development Zorevunersen Zorevunersen Regulatory Alignment & Phase 3 Plans Virtual Event for Investors & Analysts January 7, 2025 Exhibit 99.
January 7, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commissio
January 7, 2025	EX-99.1	Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome – Alignment achieved with U.S. Food Exhibit 99.1 Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome – Alignment achieved with U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for EMPEROR
December 27, 2024	EX-1	Joint Filing Agreement Exhibit 1 Joint Filing Agreement The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13D to which this Exhibit is attached, and such Schedule 13D is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.
December 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2024 Stoke Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commissi
December 6, 2024	EX-99.2	Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome – Substantial and durable reductions in convulsive seizure Exhibit 99.2 Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome – Substantial and durable reductions in convulsive seizure frequency observed in patients treated with 2 or 3 doses of 70mg followed by 45mg maintenance dosing on top of the best available anti-se
December 6, 2024	EX-99.1	Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome – Supported by evidence from clinical studies that indicate that zorevunersen may demonstrate substantial improvement over availabl Exhibit 99.1 Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome – Supported by evidence from clinical studies that indicate that zorevunersen may demonstrate substantial improvement over available therapies – – Update on the company’s plans for a global, randomized, controlled Phase 3 registrational study anticipated by year-end –
November 14, 2024	EX-99.1	AGREEMENT EX-99.1 2 tm2426483d7ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Stoke Therapeutics, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. November 14, 2024 BAKER BROS. ADV
November 14, 2024	EX-99.1	Joint Filing Agreement EX-99.1 2 tm2427858d11ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, at $0.0
November 14, 2024	SC 13G	STOK / Stoke Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13G Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.
November 14, 2024	SC 13G/A	STOK / Stoke Therapeutics, Inc. / Lynx1 Capital Management LP - STOKE THERAPEUTICS, INC. Passive Investment SC 13G/A 1 p24-3206sc13ga.htm STOKE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 86150R107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Stateme
November 14, 2024	SC 13G/A	STOK / Stoke Therapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm2427858d11sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Stoke therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 86150R107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check t
November 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 05, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commiss
November 5, 2024	EX-99.1	Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates – Company plans to provide seizure as well as cognition and behavior data from all patients treated with initial 70mg doses followed by 45mg maintenance dosing i EX-99.1 Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates – Company plans to provide seizure as well as cognition and behavior data from all patients treated with initial 70mg doses followed by 45mg maintenance dosing in studies of zorevunersen by year-end – – Discussions with FDA and global regulatory agencies related to a single global Phase 3 study of zore
November 5, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.
October 9, 2024	EX-4.3	Form of Indenture Exhibit 4.3 STOKE THERAPEUTICS, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 – DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 – THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES
October 9, 2024	EX-4.2	Form of Debt Security Exhibit 4.2 FORM OF DEBT SECURITY [Face of Security] STOKE THERAPEUTICS, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIE
October 9, 2024	EX-FILING FEES	Filing Fee Table EXHIBIT 107.1 CALCULATION OF FILING FEE TABLES Form S-3ASR (Form Type) Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Car
October 9, 2024	S-3ASR	As filed with the Securities and Exchange Commission on October 9, 2024 Table of Contents As filed with the Securities and Exchange Commission on October 9, 2024 Registration No.
September 23, 2024	SC 13D/A	STOK / Stoke Therapeutics, Inc. / Skorpios Trust Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 86150R107 (CUSIP Number) Patrik Blochlinger Chief Legal Officer Rigmora (Switzerland) Ltd Stockerstrasse 8 8002 Zurich, Switzerland +41 44
September 10, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commis
September 10, 2024	EX-99.1	IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE GERALD J. ALSID, derivatively on behalf of STOKE THERAPEUTICS, INC., Plaintiff, v. EDWARD M. KAYE, SETH L. HARRISON, ARTHUR O. TZIANABOS, ADRIAN R. KRAINER, GARRY E. MENZEL, JULIE ANNE SMITH, ARTHUR Exhibit 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE GERALD J. ALSID, derivatively on behalf of STOKE THERAPEUTICS, INC., Plaintiff, v. EDWARD M. KAYE, SETH L. HARRISON, ARTHUR O. TZIANABOS, ADRIAN R. KRAINER, GARRY E. MENZEL, JULIE ANNE SMITH, ARTHUR A. LEVIN, JENNIFER C. BURSTEIN, and SAMUEL W. HALL, Defendants, and STOKE THERAPEUTICS, INC., Nominal Defendant. ) ) ) ) ) ) ) ) ) ) )
August 7, 2024	EX-10.3	Separation and Release Agreement, by and between the Registrant and Stephen J. Tulipano, dated May 2, 2024. Exhibit 10.3 May 2, 2024 Stephen Tulipano Email: Re: Terms of Separation Dear Stephen: This letter confirms the agreement (“Agreement”) between you and Stoke Therapeutics, Inc. (the “Company”) concerning the terms of your separation and offers you the separation compensation we discussed in exchange for a general release of claims and covenant not to sue. 1. Separation Date; Resignation from Offic
August 7, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commissio
August 7, 2024	EX-99.1	Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates – FDA removes Partial Clinical Hold as company advances toward a Phase 3 registrational study of zorevunersen (STK-001) in children and adolescents with Dravet EX 99.1 Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates – FDA removes Partial Clinical Hold as company advances toward a Phase 3 registrational study of zorevunersen (STK-001) in children and adolescents with Dravet syndrome – – Company to provide an update on Phase 3 registrational plans for zorevunersen in the second half of 2024 – – Company on track to
August 7, 2024	EX-10.1	Executive Employment Agreement, by and between the Registrant and Thomas Leggett, effective as of April 23, 2024. Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), is made and entered into this 23rd day of April, 2024 (the “Effective Date”), by and between Stoke Therapeutics, Inc. (“Stoke”), and Thomas Leggett (“Executive”). WHEREAS, Stoke wishes to employ Executive to serve as its Chief Financial Officer; WHEREAS, Executive represents that Executive possesses
August 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.
August 7, 2024	EX-10.2	Change of Control Severance Agreement, by and between the Registrant and Thomas Leggett, effective as of April 23, 2024. Exhibit 10.2 CHANGE OF CONTROL SEVERANCE AGREEMENT This Change of Control Severance Agreement (the “Agreement”), is made and entered into this 23rd day of April, 2024 (the “Effective Date”), by and between Stoke Therapeutics, Inc. (“Stoke”), and Thomas Leggett (“Executive”). Recitals: R-1. Stoke and Executive are parties to an Employment Agreement dated April 23, 2024 (the “Employment Agreement,”
June 21, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission
June 17, 2024	CORRESP	STOKE THERAPEUTICS, INC. 45 Wiggins Avenue Bedford, MA 01730 June 17, 2024 STOKE THERAPEUTICS, INC. 45 Wiggins Avenue Bedford, MA 01730 June 17, 2024 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Office of Life Sciences Re: Stoke Therapeutics, Inc. Registration Statement on Form S-3 Filed June 13, 2024 File No. 333-280172 Via EDGAR - Acceleration Request Requested Date: June 20, 2024 R
June 13, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) Stoke Therapeutics, Inc.
June 13, 2024	S-3	As filed with the Securities and Exchange Commission on June 13, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on June 13, 2024 Registration No.
June 6, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission F
May 6, 2024	EX-99.1	Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates – Recent data demonstrating reductions in seizure frequency and improvements in cognition and behavior support the potential for STK-001 as a disease-modifying p EX 99.1 Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates – Recent data demonstrating reductions in seizure frequency and improvements in cognition and behavior support the potential for STK-001 as a disease-modifying potential medicine for the treatment of Dravet syndrome – – Company plans to meet with regulatory agencies to discuss registrational study desi
May 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.
May 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission F
April 29, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission
April 23, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru
April 23, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
April 18, 2024	SC 13D/A	STOK / Stoke Therapeutics, Inc. / Skorpios Trust Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
April 11, 2024	EX-FILING FEES	Filing Fee Table EXHIBIT 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Stoke Therapeutics, Inc.
April 11, 2024	S-8	As filed with the Securities and Exchange Commission on April 11, 2024 S-8 As filed with the Securities and Exchange Commission on April 11, 2024 Registration No.
March 28, 2024	FWP	Common Stock Pre-funded Warrants to Purchase Shares of Common Stock Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated March 27, 2024 Relating to Preliminary Prospectus Supplement Dated March 26, 2024 Registration Statement No.
March 28, 2024	EX-4.1	Form of Pre-Funded Warrant. Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: April 2, 2024 STOKE THERAPEUCTICS, INC. Stoke Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered ass
March 28, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission
March 28, 2024	EX-99.1	Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering Exhibit 99.1 Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering BEDFORD, Mass., March 27, 2024 (BUSINESS WIRE) – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the pricing of its upsized underwritten public offering
March 28, 2024	424B5	Sole Book-Running Manager J.P. Morgan Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-265107 Prospectus supplement (To prospectus dated May 31, 2022) 5,555,557 shares of Common Stock Pre-funded Warrants to Purchase 3,703,730 Shares of Common Stock Common stock We are offering 5,555,557 shares of our common stock, par value $0.0001 per share and, in lieu of common stock to certain investors that so choose, pre-f
March 28, 2024	EX-1.1	Underwriting Agreement dated March 27, 2024, by and between the Company and J.P. Morgan Securities LLC. Exhibit 1.1 Execution Version Stoke Therapeutics, Inc. 5,555,557 Shares of Common Stock and Pre-Funded Warrants to Purchase 3,703,730 Shares of Common Stock Underwriting Agreement March 27, 2024 J.P. Morgan Securities LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Stoke T
March 26, 2024	424B5	Sole Book-Running Manager J.P. Morgan Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-265107 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, as amended, but the information in this prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus a
March 25, 2024	EX-99.1	Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results – As of December 31, 2023, Company had $201.4 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to the end of 2025 – EX 99.1 Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results – As of December 31, 2023, Company had $201.4 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to the end of 2025 – BEDFORD, Mass., March 25, 2024 – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe
March 25, 2024	EX-99.1	Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome – Phase 1/2a End of Study Data: 70mg doses demonstrated substantial an Exhibit 99.1 Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome – Phase 1/2a End of Study Data: 70mg doses demonstrated substantial and sustained reductions in convulsive seizure frequency on top of the best available anti-seizure medicines; Median reductions of 85% (n=1
March 25, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission
March 25, 2024	EX-10.12	Lease Agreement, dated as of September 8, 2021, by and between ARE-MA Region No. 24, LLC and the Registrant, as amended to date. Exhibit 10.12 LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made this 8 day of September, 2021, between ARE‑MA REGION NO. 24, LLC, a Delaware limited liability company (“Landlord”), and STOKE THERAPEUTICS, INC., a Delaware corporation (“Tenant”). Building: 45-47 Wiggins Avenue, Bedford, MA 01730 Premises: That portion of (i) the Building known as Suite 200, containing approximately 23,000
March 25, 2024	EX-97	Compensation Recovery Policy Exhibit 97 Stoke Therapeutics, Inc. Compensation Recovery Policy (Adopted September 19, 2023) The Board has determined that it is in the best interests of the Company and its stockholders to adopt this Policy enabling the Company to recover from specified current and former Company executives certain incentive-based compensation in the event of an accounting restatement resulting from material non
March 25, 2024	EX-4.2	Description of Common Stock Registered Under Section 12 of the Securities Exchange Act of 1934. Exhibit 4.2 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of December 31, 2020, Stoke Therapeutics, Inc. (the “Company,” “we,” or “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following description summarizes the mo
March 25, 2024	10-K	f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38938 Stoke Therape
March 25, 2024	EX-3.1	Restated Certificate of Incorporation of the Registrant, as amended Exhibit 3.1 STOKE THERAPEUTICS, INC. RESTATED CERTIFICATE OF INCORPORATION Stoke Therapeutics, Inc., a Delaware corporation, hereby certifies as follows: 1. The name of the corporation is “Stoke Therapeutics, Inc.” The date of the filing of its original Certificate of Incorporation with the Secretary of State was June 13, 2014 under the name ASOthera Pharmaceuticals, Inc. 2. The Restated Certifica
March 25, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission
March 25, 2024	EX-99.2	Agenda Introduction Eric Rojas, Head of Investor Relations Introductory Remarks Edward M. Kaye, M.D., Chief Executive Officer Analysis of Phase 1/2a and Open-Label Extension (OLE) Studies of STK-001 Barry Ticho, M.D., Ph.D., Chief Medical Officer Kim Analysis of STK-001 for the Treatment of Dravet Syndrome Stoke Therapeutics March 25, 2024 Exhibit 99.
February 26, 2024	SC 13G	STOK / Stoke Therapeutics, Inc. / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment SC 13G 1 stok22624.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Stoke Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 86150R107 (CUSIP Number) January 04, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat
February 26, 2024	SC 13G/A	STOK / Stoke Therapeutics, Inc. / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 86150R107 (CUSIP Number) December 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi
February 14, 2024	SC 13G/A	STOK / Stoke Therapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm245846d12sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3) Stoke therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check t
February 14, 2024	SC 13G/A	STOK / Stoke Therapeutics, Inc. / RTW INVESTMENTS, LP - STOKE THERAPEUTICS, INC. Passive Investment SC 13G/A 1 p24-0444sc13ga.htm STOKE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statemen
February 14, 2024	SC 13G/A	STOK / Stoke Therapeutics, Inc. / Lynx1 Capital Management LP - STOKE THERAPEUTICS, INC. Passive Investment SC 13G/A 1 p24-0771sc13ga.htm STOKE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statemen
February 14, 2024	EX-99.1	Joint Filing Agreement EX-99.1 2 tm245846d12ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, at $0.00
February 9, 2024	SC 13G/A	STOK / Stoke Therapeutics, Inc. / MORGAN STANLEY - MS AMENDMENT Passive Investment SC 13G/A 1 StokeTherapeuticsSTOK.txt MS AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* STOKE THERAPEUTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 86150R107 - (CUSIP Number) December 31, 2023 - (Date Of Event which Requires Filing of this Statement) Check the appr
January 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Stoke Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commissio
January 8, 2024	EX-99.1	Disclaimer This presentation has been prepared by Stoke Therapeutics, Inc. ( Stoke or us ) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise EX-99.1 Exhibit 99.1 Stoke Therapeutics NASDAQ: STOK Edward M. Kaye, M.D. Chief Executive Officer nd 42 Annual J.P. Morgan Healthcare Conference January 10, 2024 © Copyr ©i g Ch op t 2024 yrightS 2024 toke T Sh tok era ep T e h u e tr ic as peutic1 s Disclaimer This presentation has been prepared by Stoke Therapeutics, Inc. ( Stoke or us ) for informational purposes only and not for any other purp
December 14, 2023	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commiss
December 5, 2023	SC TO-I/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 3) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 STOKE THERAPEUTICS, INC. (Name of Su UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 3) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 STOKE THERAPEUTICS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 86150
December 1, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2023 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commissi
December 1, 2023	EX-99.1	Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting – Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages Exhibit 99.1 Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting – Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease mo
November 17, 2023	EX-99.(A)(1)(D)	Form of Reminder Email to Eligible Employees Regarding the Exchange Offer Deadline EX-99.(a)(1)(D) Exhibit (a)(1)(D) As an Eligible Employee in Stoke Therapeutics’ Exchange Program to exchange Eligible Options for New RSUs (restricted stock units), we are pleased to inform you that the Exchange Offer is still open and you can make or change your election(s) until the Exchange Offer expires at 11:59 p.m., Eastern Daylight Time, on December 1, 2023. To access the Exchange Program
November 17, 2023	SC TO-I/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 2) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 STOKE THERAPEUTICS, INC. (Name of Su SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 2) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 STOKE THERAPEUTICS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securit
November 17, 2023	CORRESP	* * * * * * * Julia Forbess [email protected] \| 415.875.2420 November 17, 2023 VIA EDGAR AND OVERNIGHT DELIVERY U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Christina Chalk Shane Callaghan Re: Stoke Therapeutics, Inc. Schedule TO-I Filed November 2, 2023 File No. 005-91051 Ladies and Gentlemen: On behalf of St
November 9, 2023	SC TO-I/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 1) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 STOKE THERAPEUTICS, INC. (Name of Subj UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 1) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 STOKE THERAPEUTICS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 86150R1
November 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2023 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commiss
November 7, 2023	EX-99.1	Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates – STK-001: Q1 2024 readout expected to include end of Phase 1/2a study results and longer-term data on the effects of repeat dosing on seizure frequency, cogniti EX 99.1 Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates – STK-001: Q1 2024 readout expected to include end of Phase 1/2a study results and longer-term data on the effects of repeat dosing on seizure frequency, cognition, and behavior from the ongoing open-label extension (OLE) studies – – STK-001: Company then plans to meet with regulators to discuss a Phas
November 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.
November 6, 2023	SC 13G	STOK / Stoke Therapeutics Inc / Lynx1 Capital Management LP - STOKE THERAPEUTICS, INC. Passive Investment SC 13G 1 p23-2664sc13g.htm STOKE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 86150R107 (CUSIP Number) October 26, 2023 (Date of Event Which Requires Filing of this Statement) Chec
November 6, 2023	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 p23-2664exhibit99.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agr
November 2, 2023	EX-99.(A)(1)(D)	Form of Reminder Email to Eligible Employees Regarding the Exchange Offer Deadline EX-99.(a)(1)(D) Exhibit (a)(1)(D) As an Eligible Employee in Stoke Therapeutics’ Exchange Program to exchange Eligible Options for New RSUs (restricted stock units), we are pleased to inform you that the Exchange Offer is still open and you can make or change your election(s) until the Exchange Offer expires at 11:59 p.m., Eastern Daylight Time, on December 1, 2023. To access the Exchange Program
November 2, 2023	EX-99.(A)(1)(E)	Form of Frequently Asked Questions EX-99.(a)(1)(E) Exhibit (a)(1)(E) What is the Offer to Exchange Eligible Options for Restricted Stock Units (RSUs)? The exchange offer (the “Exchange Offer”) is an offer for Eligible Employees (as defined below) to exchange significantly out-of-the-money or “underwater” stock options for new restricted stock units (“RSUs”) on an approximately value-neutral basis. Who is eligible to participate in
November 2, 2023	EX-99.(A)(1)(A)	Offer to Exchange Eligible Options for New Restricted Stock Units, dated November 2, 2023 EX-99.(a)(1)(A) Exhibit (a)(1)(A) NOVEMBER 2, 2023 STOKE THERAPEUTICS, INC. SUMMARY TERM SHEET — OVERVIEW OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW RESTRICTED STOCK UNITS THIS OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M., EASTERN TIME, ON DECEMBER 1, 2023, UNLESS EXTENDED By this Offer to Exchange Eligible Options for restricted stock units (as the context requires, this document and the
November 2, 2023	EX-99.(A)(1)(G)	Story Boards for Employee Education Videos EX-99.(a)(1)(G) Exhibit (a)(1)(G) Scene 1 (00m00s - 00m06s) Description: equitv.aon.com/viewer/StokeTherapeutics23/UWSO/1a1672bbf 8df4236 Words on screen: Stoke Therapeutics Option Exchange Program Overview Storyboard: Stoke Therapeutics \| UWSO \| StokeTherapeutics’ Option Exchange Program Overview (2023) Scene 2 (00m06s - 00m11s) Script: Welcome to this video that will explain the Stoke Therapeuti
November 2, 2023	EX-99.(A)(1)(B)	Form of Announcement to Eligible Employees that Exchange Program has Opened EX-99.(a)(1)(B) Exhibit (a)(1)(B) We are pleased to announce that Stoke Therapeutics’ Option Exchange Program opens today. You are receiving this email because you are eligible to exchange certain underwater options for a fewer number of new Restricted Stock Units (RSUs) with a substantially similar value. The Exchange Offer is currently scheduled to remain open through 11:59 p.m., Eastern Dayligh
November 2, 2023	EX-99.(A)(1)(C)	Form of Email Confirming Receipt of Election(s) EX-99.(a)(1)(C) Exhibit (a)(1)(C)
November 2, 2023	SC TO-I	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 STOKE THERAPEUTICS, INC. (Name of Subject Company (Issue SC TO-I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 STOKE THERAPEUTICS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 86150R107 (CUSIP
November 2, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Schedule TO-I (Form Type) Stoke Therapeutics, Inc.
November 2, 2023	EX-99.(A)(1)(I)	Script for Power Point Deck EX-99.(a)(1)(I) Exhibit (a)(1)(I) Stoke Therapeutics – Stock Option Exchange Program Presentation Introduction: Good afternoon everyone, and thank you for joining us today for a presentation about Stoke’s stock option exchange program. As many of you know, I am Jon Allan, General Counsel here at Stoke, and I am joined today by John Hammond from our advisors at Aon who will walk you through the exc
November 2, 2023	EX-99.(A)(1)(F)	Screenshots from Exchange Offer Website EX-99.(a)(1)(F) Exhibit (a)(1)(F) Website Screenshots Document Library page – more documents will be listed as needed
November 2, 2023	EX-99.(A)(1)(H)	Stoke Therapeutics Stock Option Exchange Program PowerPoint Deck EX-99.(a)(1)(H) Exhibit (a)(1)(H) Stoke Therapeutics Stock Option Exchange Program November 2023 © Copyr © igh Cot p2023 yrigh t S2023 toke T Sh to er ke ap T eh ue tic ras peutics 1 Agenda • Introductions and Overview • The Basics • How an Option Exchange Works • Eligibility • RSU Terms • Considering Your Choice • Important Disclaimers • Q&A © Copyright 2023 Stoke Therapeutics 2 Quick Intro • Joh
October 26, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organiz
September 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
September 20, 2023	EX-99.1	Stoke Therapeutics Appoints Ian Smith to its Board of Directors – Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – Exhibit 99.1 Stoke Therapeutics Appoints Ian Smith to its Board of Directors – Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – BEDFORD, Mass., September 20, 2023 – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protei
September 20, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commis
September 18, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (
August 7, 2023	EX-99.1	Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates – STK-001: Additional data from patients treated with single and multiple doses (70mg) along with data from open-label extension studies (30mg, 45mg) anticipate EX 99.1 Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates – STK-001: Additional data from patients treated with single and multiple doses (70mg) along with data from open-label extension studies (30mg, 45mg) anticipated in Q1 2024 – – STK-001: Company plans to share an update on Phase 3 planning in 1H 2024 – – STK-002: Company received authorization to initi
August 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2023 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commissio
August 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.
July 25, 2023	EX-99.2	Agenda Introduction Eric Rojas, Head of Investor Relations Introductory Remarks Edward M. Kaye, M.D., Chief Executive Officer Phase 1/2a Interim Analysis Barry Ticho, M.D., Ph.D., Chief Medical Officer Kimberly Parkerson, M.D., Ph.D., Head of Neurolo EX-99.2 Analysis of STK-001 for the Treatment of Dravet Syndrome Stoke Therapeutics July 25, 2023 Exhibit 99.2 Agenda Introduction Eric Rojas, Head of Investor Relations Introductory Remarks Edward M. Kaye, M.D., Chief Executive Officer Phase 1/2a Interim Analysis Barry Ticho, M.D., Ph.D., Chief Medical Officer Kimberly Parkerson, M.D., Ph.D., Head of Neurology Clinical Development Closing Remarks
July 25, 2023	EX-99.1	Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome – EX-99.1 Exhibit 99.1 Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome – Totality of data from these ongoing studies suggest clinical benefit for patients ages 2 to 18 years old, including reductions in
July 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2023 Stoke Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2023 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizati
June 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 Stoke Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizati
May 24, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
May 4, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2023 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission F
May 4, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.
May 4, 2023	EX-4	Registration Rights Agreement, by and among the Registrant, Blue Horizon Enterprise Ltd. and Ezbon International Limited, dated May 3, 2023. Exhibit 4.1 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made as of May 3, 2023 by and among Stoke Therapeutics, Inc. a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have
May 4, 2023	EX-99	Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates – Company on-track to report new data from the ongoing Phase 1/2a clinical studies of STK-001 in children and adolescents with Dravet syndrome in mid-2023 – – Da EX 99.1 Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates – Company on-track to report new data from the ongoing Phase 1/2a clinical studies of STK-001 in children and adolescents with Dravet syndrome in mid-2023 – – Data readout will focus on safety and seizure frequency results for up to 16 patients who received three doses of 45mg of STK-001 – – Company pl
April 27, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
April 27, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru
April 17, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (
April 13, 2023	EX-99.1	2023 Inducement Plan, and forms of award agreements. EX-99.1 Exhibit 99.1 STOKE THERAPEUTICS, INC. 2023 INDUCEMENT PLAN 1. PURPOSE. The purpose of this Plan is to provide incentives to attract and motivate eligible employees whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries, and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Company’
April 13, 2023	S-8	As filed with the Securities and Exchange Commission on April 13, 2023 As filed with the Securities and Exchange Commission on April 13, 2023 Registration No.
April 13, 2023	EX-FILING FEES	Filing Fees Table EX-FILING FEES Exhibit 107.1 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Commo
March 22, 2023	S-8	As filed with the Securities and Exchange Commission on March 22, 2023 S-8 As filed with the Securities and Exchange Commission on March 22, 2023 Registration No.
March 22, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par val
March 15, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizat
March 15, 2023	EX-99.1	Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome – Dosing anticipated to start in the coming weeks – EX-99.1 Exhibit 99.1 Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome – Dosing anticipated to start in the coming weeks – – Company remains on track for its planned data readouts from the Phase 1/2a MONARCH and ADMIRAL studies in 2023 – BEDFORD, Mass
March 6, 2023	EX-99.1	Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates – Company expects to complete Phase 1/2a studies of STK-001 in children and adolescents with Dravet syndrome in 2023 in order to initiate a P Exhibit 99.1 Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates – Company expects to complete Phase 1/2a studies of STK-001 in children and adolescents with Dravet syndrome in 2023 in order to initiate a Phase 3 program in 2024 – – Company on track to provide additional safety and seizure frequency data from patients who received multiple 4
March 6, 2023	EX-10.3	2019 Equity Incentive Plan and forms of award agreements thereunder Exhibit 10.3 STOKE THERAPEUTICS, INC. 2019 EQUITY INCENTIVE PLAN 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain, and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries, and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Com
March 6, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizati
March 6, 2023	10-K	Form 10-K f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38938 Stoke Therape
February 14, 2023	SC 13G/A	STOK / Stoke Therapeutics Inc / RTW INVESTMENTS, LP - STOKE THERAPEUTICS, INC. Passive Investment SC 13G/A 1 p23-0490sc13ga.htm STOKE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement
February 9, 2023	SC 13G/A	STOK / Stoke Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Stoke Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 86150R107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is file
February 3, 2023	SC 13G/A	STOK / Stoke Therapeutics Inc / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm235383d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) Stoke therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check th
February 3, 2023	EX-3.1	Restated Bylaws of the Registrant Exhibit 3.1 STOKE THERAPEUTICS, INC. (a Delaware corporation) AMENDED AND RESTATED BYLAWS As Amended and Restated on February 2, 2023 STOKE THERAPEUTICS, INC. (a Delaware corporation) AMENDED AND RESTATED BYLAWS TABLE OF CONTENTS Article I: STOCKHOLDERS 5 Section 1.1: Annual Meetings 5 Section 1.2: Special Meetings 5 Section 1.3: Notice of Meetings 5 Section 1.4: Adjournments 5 Section 1.5: Quorum
February 3, 2023	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organiz
February 3, 2023	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, at $0.0001 par value per share, of Stoke Therapeutics
January 25, 2023	SC 13G/A	STOK / Stoke Therapeutics Inc / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment SC 13G/A 1 stoka112523.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 86150r107 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the app
January 9, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organiza
January 9, 2023	EX-99.1	Disclaimer This presentation has been prepared by Stoke Therapeutics, Inc. ( Stoke or us ) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise EX-99.1 2 d427248dex991.htm EX-99.1 Exhibit 99.1 Stoke Therapeutics NASDAQ: STOK Edward M. Kaye, M.D. Chief Executive Officer st 41 Annual J.P. Morgan Healthcare Conference January 10, 2023 © Copy © Copy right 20 ri23 ght S20 toke 23 Therape Stoke Therape utics utic1 s Disclaimer This presentation has been prepared by Stoke Therapeutics, Inc. ( Stoke or us ) for informational purposes only and not
December 2, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2022 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organiz
December 2, 2022	EX-99.1	Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting – Single and multip Exhibit 99.1 Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting ? Single and multiple doses of STK-001 up to 45mg were well-tolerated ? ? 55% median reduction from baseline in convulsive seizure frequency was observed am
November 14, 2022	EX-99.1	Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates – Company announces positive interim data from the ongoing Phase 1/2a clinical studies of STK-001 in children and adolescents with Dravet syndrome – – Single and Exhibit 99.1 Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates ? Company announces positive interim data from the ongoing Phase 1/2a clinical studies of STK-001 in children and adolescents with Dravet syndrome ? ? Single and multiple doses of STK-001 up to 45mg were well-tolerated ? ? 55% median reduction from baseline in convulsive seizure frequency was obse
November 14, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Stoke Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organi
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.
November 14, 2022	EX-99.2	Agenda Introduction Eric Rojas, Head of Investor Relations Introductory Remarks Edward M. Kaye, M.D., Chief Executive Officer Phase 1/2a Interim Analysis Barry Ticho, M.D., Ph.D., Chief Medical Officer Closing Remarks Edward M. Kaye, M.D., Chief Exec Interim Analysis of STK-001 for the Treatment of Dravet Syndrome Stoke Therapeutics November 14, 2022 Exhibit 99.
August 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.
August 8, 2022	EX-99.1	Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates – In the fourth quarter, the Company plans to announce interim safety, pharmacokinetic (PK), and cerebrospinal fluid (CSF) drug exposure data from approximately Exhibit 99.1 Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates ? In the fourth quarter, the Company plans to announce interim safety, pharmacokinetic (PK), and cerebrospinal fluid (CSF) drug exposure data from approximately 40 patients in the ongoing clinical studies of STK-001 in children and adolescents with Dravet syndrome ? ? Analysis will also include s
August 8, 2022	EX-10.1	Scientific Advisory Board Agreement by and between the Registrant and Adrian Krainer, Ph.D., dated June 1, 2022. Exhibit 10.1 STOKE THERAPEUTICS, INC. SCIENTIFIC ADVISORY BOARD AGREEMENT This SCIENTIFIC ADVISORY BOARD Agreement (this ?Agreement?) is entered into as of June 1, 2022 (the ?Effective Date?) between Stoke Therapeutics, Inc., a Delaware corporation having offices at 45 Wiggins Avenue, Bedford, MA 01730 (?Stoke?) and Adrian Krainer, Ph.D. (?Advisor?). Advisor has unique skills and knowledge pertine
August 8, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizat
June 8, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizatio
May 26, 2022	CORRESP	STOKE THERAPEUTICS, INC. 45 Wiggins Avenue Bedford, MA 01730 May 26, 2022 STOKE THERAPEUTICS, INC. 45 Wiggins Avenue Bedford, MA 01730 May 26, 2022 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Office of Life Sciences Re: Stoke Therapeutics, Inc. Registration Statement on Form S-3 Filed May 20, 2022 File No. 333-265107 Via EDGAR - Acceleration Request Requested Date: May 31, 2022 Reque
May 20, 2022	EX-4.3	Form of Debt Security Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] STOKE THERAPEUTICS, INC. [If applicable, insert?FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS ?PRINCIPAL AMOUNT?), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MA
May 20, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Fee Filing Tables Form S-3 (Form Type) Stoke Therapeutics, Inc.
May 20, 2022	EX-4.4	Form of Indenture Exhibit 4.4 STOKE THERAPEUTICS, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 ? DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 ? THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 5 2.3. EXEC
May 20, 2022	S-3	As filed with the Securities and Exchange Commission on May 20, 2022 Table of Contents As filed with the Securities and Exchange Commission on May 20, 2022 Registration No.
May 20, 2022	EX-1.2	Controlled Equity OfferingSM Sales Agreement, dated May 20, 2022, by and between the Registrant and Cantor Fitzgerald & Co. Exhibit 1.2 STOKE THERAPEUTICS, INC. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement May 20, 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Stoke Therapeutics, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?), as follows: 1. Issu
May 20, 2022	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2022 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizatio
May 10, 2022	EX-10.1	License and Collaboration Agreement, dated as of January 9, 2022, by and between Acadia Pharmaceuticals Inc. and the Registrant. Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED Execution Version LICENSE AND COLLABORATION AGREEMENT by and between Stoke Therapeutics, Inc. and Acadia Pharmaceuticals Inc. January 9, 2022 Execution Version LICENSE AND COLLABORATION AG
May 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizatio
May 10, 2022	EX-99.1	Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates – 2H 2022 clinical data readout on track for patients with Dravet syndrome who received multiple doses of STK-001 (30mg) in Phase 1/2a clinical studies MONARCH, Exhibit 99.1 Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates ? 2H 2022 clinical data readout on track for patients with Dravet syndrome who received multiple doses of STK-001 (30mg) in Phase 1/2a clinical studies MONARCH, ADMIRAL, and SWALLOWTAIL ? ? Recent preclinical data support ongoing development of STK-002 as the first potential disease-modifying appr
May 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q X` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.
April 26, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A 1 d295502ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Prox
April 26, 2022	DEF 14A	Definitive Proxy Statement DEF 14A 1 d295502ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confident
March 14, 2022	S-8	As filed with the Securities and Exchange Commission on March 14, 2022 As filed with the Securities and Exchange Commission on March 14, 2022 Registration No.
March 14, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 ? Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.000
March 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizat
March 10, 2022	EX-10.13	Scientific Advisory Board Agreement by and between the Registrant and Adrian Krainer, Ph.D., dated June 1, 2021 Exhibit 10.13 STOKE THERAPEUTICS, INC. SCIENTIFIC ADVISORY BOARD AGREEMENT This SCIENTIFIC ADVISORY BOARD Agreement (this ?Agreement?) is entered into as of June 1, 2021 (the ?Effective Date?) between Stoke Therapeutics, Inc., a Delaware corporation having offices at 45 Wiggins Avenue, Bedford, MA 01730 (?Stoke?) and Adrian Krainer, Ph.D. (?Advisor?). Advisor has unique skills and knowledge pertin
March 10, 2022	10-K	s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38938 Stoke Therape
March 10, 2022	EX-99.1	Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates – Enrollment and dosing ongoing in the Phase 1/2a MONARCH and ADMIRAL studies of STK-001 in children and adolescents with Dravet syndrome – – Exhibit 99.1 Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates ? Enrollment and dosing ongoing in the Phase 1/2a MONARCH and ADMIRAL studies of STK-001 in children and adolescents with Dravet syndrome ? ? Company remains on track to provide additional clinical data in 2H 2022 from patients treated with multiple ascending doses of STK-001 a
February 17, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2022 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organi
February 14, 2022	SC 13G/A	STOK / Stoke Therapeutics Inc / Redmile Group, LLC - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) STOKE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p
February 14, 2022	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, at $0.0001 par value per share, of Stoke Therapeutics
February 14, 2022	SC 13G/A	STOK / Stoke Therapeutics Inc / RTW INVESTMENTS, LP - STOKE THERAPEUTICS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursu
February 10, 2022	SC 13G	STOK / Stoke Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Stoke Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 86150R107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13d-1(b) ?
January 24, 2022	SC 13G	STOK / Stoke Therapeutics Inc / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment SC 13G 1 stok12422.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Stoke Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 86150r107 (CUSIP Number) January 19, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat
January 10, 2022	EX-99.2	Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases - Establishes co-development and co-commercialization agreement for Stoke’s SYNGAP1 p Exhibit 99.2 Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases - Establishes co-development and co-commercialization agreement for Stoke?s SYNGAP1 preclinical program - Acadia receives exclusive worldwide licenses for two additional preclinical programs: Rett syndrome (MECP2) and undi
January 10, 2022	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2022 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organiza
January 10, 2022	EX-99.1	Disclaimer This presentation has been prepared by Stoke Therapeutics, Inc. (“Stoke” or “our”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promi Exhibit 99.1 Stoke Therapeutics NASDAQ: STOK Edward M. Kaye, M.D. Chief Executive Officer th 40 Annual J.P. Morgan Healthcare Conference January 10, 2022 ? Copyr ? igh Cot p2022 yrigh t S2022 toke T Sh to er ke ap T eh ue tic ras peutics 1 Disclaimer This presentation has been prepared by Stoke Therapeutics, Inc. (?Stoke? or ?our?) for informational purposes only and not for any other purpose. Not
December 17, 2021	8-K	Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organi
December 3, 2021	EX-99.1	Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting – Single doses of STK-001 up to 30mg and multiple doses of 20mg Exhibit 99.1 Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting ? Single doses of STK-001 up to 30mg and multiple doses of 20mg were well tolerated with no safety concerns related to study drug ? ? 70.6% (12/17) of patients treated with STK-001 experienced a reduct
December 3, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2021 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organiz
November 8, 2021	EX-99.1	Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates – Company nominates STK-002 as clinical candidate for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder – Exhibit 99.1 Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates ? Company nominates STK-002 as clinical candidate for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder ? ? Additional data from an interim analysis of the Phase 1/2a MONARCH study of STK-001 including 20mg multiple ascending dose (MAD) seizur
November 8, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organiz
November 8, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.
November 8, 2021	EX-10.1	Lease Agreement, dated as of September 8, 2021, by and between ARE-MA Region No. 24, LLC and the Registrant. Exhibit 10.1 LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made this 8 day of September, 2021, between ARE?MA REGION NO. 24, LLC, a Delaware limited liability company (?Landlord?), and STOKE THERAPEUTICS, INC., a Delaware corporation (?Tenant?). Building: 45-47 Wiggins Avenue, Bedford, MA 01730 Premises: That portion of (i) the Building known as Suite 200, containing approximately 23,000
November 8, 2021	EX-10.2	Amendment to Sublease dated as of September 8, 2021, by and between Homology Medicines, Inc., and the Registrant. Exhibit 10.2 AMENDMENT TO SUBLEASE THIS AMENDMENT TO SUBLEASE (this ?Amendment?) is dated as of September 8, 2021 (the ?Effective Date?) by and between Homology Medicines, Inc., a Delaware corporation (?Sublessor?), and Stoke Therapeutics, Inc., a Delaware corporation ("Subtenant"). Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to them in the Sublease. R
September 21, 2021	EX-99.1	Agenda Introduction Eric Rojas, Head of Investor Relations Disease Overview, Patient Need, and STK-001 Mechanism of Action Edward M. Kaye, M.D., Chief Executive Officer Phase 1/2a MONARCH Interim Analysis Barry Ticho, M.D., Ph.D., Chief Medical Offic MONARCH study in Dravet Syndrome Interim Analysis September 21, 2021 Exhibit 99.1 Agenda Introduction Eric Rojas, Head of Investor Relations Disease Overview, Patient Need, and STK-001 Mechanism of Action Edward M. Kaye, M.D., Chief Executive Officer Phase 1/2a MONARCH Interim Analysis Barry Ticho, M.D., Ph.D., Chief Medical Officer Closing Remarks Edward M. Kaye, M.D., Chief Executive Officer Q&A
September 21, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2021 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organ
September 9, 2021	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2021 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organi
August 10, 2021	EX-10.1	Lease Agreement, by and between MIT 139 Main Street Leasehold LLC, and the Registrant., as amended to date. EXHIBIT 10.1 139 Main street CAMBRIDGE, MASSACHUSETTS LEASE SUMMARY SHEET Execution Date: January 2, 2019 Tenant: Stoke Therapeutics, Inc. a Delaware corporation Tenant?s Mailing Address Prior to Occupancy: 3 Preston Court Suite 102 Bedford, MA 01730 Landlord: MIT 139 Main Street Leasehold LLC, a Massachusetts limited liability company Building: 139 Main Street, Cambridge, Massachusetts. The Build
August 10, 2021	EX-99.1	Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates – Dosing up to 30mg complete in the single ascending dose (SAD) portion in the Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndr Exhibit 99.1 Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates ? Dosing up to 30mg complete in the single ascending dose (SAD) portion in the Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndrome; Enrollment and dosing in the multiple ascending dose (MAD) portion ongoing ? ? Third quarter data readout will include 3-month safet
August 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organiza
August 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.
June 30, 2021	SC 13D	STOK / Stoke Therapeutics Inc / Skorpios Trust Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
June 29, 2021	SC 13D/A	STOK / Stoke Therapeutics Inc / ATP Life Science Ventures, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 86150R107 (CUSIP Number) Daniel P. Finkelman General Counsel Apple Tree Partners 230 Park Avenue, 28th Floor New York, NY 10169 (212) 468
June 9, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2021 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizatio
May 14, 2021	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No.
May 10, 2021	EX-99.1	Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates – Enrollment complete in single ascending dose (SAD) portion (10mg, 20mg, 30mg) of Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet sy Exhibit 99.1 Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates ? Enrollment complete in single ascending dose (SAD) portion (10mg, 20mg, 30mg) of Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndrome; Interim analysis planned for the third quarter ? ? Enrollment and dosing ongoing in the 20mg multiple ascending dose (MAD) portio
May 10, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.
May 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizatio
April 26, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru
April 26, 2021	DEF 14A	- DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (
March 19, 2021	S-8	- S-8 As filed with the Securities and Exchange Commission on March 19, 2021 Registration No.
March 9, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38938 Stoke Therapeut
March 9, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2021 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizati
March 9, 2021	EX-4.3	Description of Common Stock Registered Under Section 12 of the Securities Exchange Act of 1934. Exhibit 4.3 Description of the Registrant?s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of December 31, 2020, Stoke Therapeutics, Inc. (the ?Company,? ?we,? or ?our?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock. The following description summarizes the mo
March 9, 2021	EX-10.7	Change of Control and Severance Agreement, by and between the Registrant and Barry Ticho, effective as of October 21, 2020. Exhibit 10.10 CHANGE OF CONTROL SEVERANCE AGREEMENT This Change of Control Severance Agreement (the ?Agreement?), is made and entered into this 21st day of October, 2020 (the ?Effective Date?), by and between Stoke Therapeutics, Inc. (?Stoke?), and Barry Ticho (?Executive?). Recitals: R-1. Stoke and Executive are parties to an Amended and Restated Employment Agreement dated October 21, 2020, (the
March 9, 2021	EX-99.1	Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates – First patient dosed in the multiple ascending dose portion of Phase 1/2a MONARCH study of STK-001 in Dravet syndrome – – Preliminary safety and PK data from t Exhibit 99.1 Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates ? First patient dosed in the multiple ascending dose portion of Phase 1/2a MONARCH study of STK-001 in Dravet syndrome ? ? Preliminary safety and PK data from the single ascending dose portion of MONARCH still expected in H2 2021 ? ? As of December 31, 2020, Company had $287.5 million in cash, ca
March 9, 2021	EX-10.10	Amended and Restated Executive Employment Agreement, by and between the Registrant and Barry Ticho, effective as of October 21, 2020. Exhibit10.7 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the ?Agreement?), is made and entered into this 21st day of October, 2020 (the ?Effective Date?), by and between Stoke Therapeutics, Inc. (?Stoke?), and Barry Ticho (?Executive?). WHEREAS, Stoke and Executive entered into that certain Employment Agreement dated September 11, 20
February 16, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 1)* Stoke Therapeut SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 1)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 2020 (Date o
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 20220 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th
February 16, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Stoke therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) (CUSIP Number) Dec UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Stoke therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi
February 16, 2021	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, at $0.0001 par value per share, of Stoke Therapeutics

STOK / Stoke Therapeutics, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings